CompuMed, Inc (CMPD) Fair Value & Analysis
Healthcare · US · Market cap $7.8M
Fair value as of: Jun 24, 2026
Analysis
CompuMed, Inc (CMPD) currently trades at $6.04, while our model-based Fair Value estimate is $9.11 — implying the stock looks roughly 50.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
CompuMed, Inc. provides diagnostic telemedicine solutions in the United States. It offers a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including echocardiogram, ECG/EKG, nuclear cardiology, cardiac CT and MRI, MUGA scan, cardiac catheterization, pediatric, stress testing, and holter/event monitor; and teleradiology reading and interpretation services, such as X-ray, ultrasound, chest CT, MRI, measurement, and on demand consult. The company also provides telepathology reading and interpretation services for liver, renal/kidney, pancreas, and tissue; and pulmonology reading and interpretation services comprising bronchoscopy, 3D rendering, measurement, and lung management. In addition, it provides support services; and operates CompuMed, a cloud-based portal that allows to view, manage, and share your case data. The company serves organ donation/transplant, correctional healthcare, hospitals, and rural hospital telemedicine m…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is CompuMed, Inc (CMPD) undervalued?
What is the fair value of CMPD?
What is the quality score of CMPD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.